We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $70.90, moving +0.14% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.08%. Meanwhile, the Dow lost 0.34%, and the Nasdaq, a tech-heavy index, added 11.55%.
Prior to today's trading, shares of the pharmaceutical had gained 1.8% over the past month. This has outpaced the Medical sector's gain of 0.62% and the S&P 500's loss of 1.03% in that time.
Wall Street will be looking for positivity from Astrazeneca as it approaches its next earnings report date. In that report, analysts expect Astrazeneca to post earnings of $0.71 per share. This would mark a year-over-year decline of 15.48%. Our most recent consensus estimate is calling for quarterly revenue of $11.4 billion, down 5.09% from the year-ago period.
Investors might also notice recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.19% lower. Astrazeneca is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 19.46 right now. This valuation marks a premium compared to its industry's average Forward P/E of 14.68.
Also, we should mention that AZN has a PEG ratio of 1.33. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.74 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
Astrazeneca (AZN - Free Report) closed the most recent trading day at $70.90, moving +0.14% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.08%. Meanwhile, the Dow lost 0.34%, and the Nasdaq, a tech-heavy index, added 11.55%.
Prior to today's trading, shares of the pharmaceutical had gained 1.8% over the past month. This has outpaced the Medical sector's gain of 0.62% and the S&P 500's loss of 1.03% in that time.
Wall Street will be looking for positivity from Astrazeneca as it approaches its next earnings report date. In that report, analysts expect Astrazeneca to post earnings of $0.71 per share. This would mark a year-over-year decline of 15.48%. Our most recent consensus estimate is calling for quarterly revenue of $11.4 billion, down 5.09% from the year-ago period.
Investors might also notice recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.19% lower. Astrazeneca is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 19.46 right now. This valuation marks a premium compared to its industry's average Forward P/E of 14.68.
Also, we should mention that AZN has a PEG ratio of 1.33. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.74 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.